IceCure Medical (ICCM) has filed for regulatory approval with the Medical Device Division of Israel’s Ministry of Health for its single cryoprobe cryoablation system, the XSense System and CryoProbes. The filing contains a request for approval of all indications for which ProSense(R) has already received approval in Israel, including general surgery, dermatology, neurology, including cryoanalgesia, thoracic surgery, ear, nose, throat, gynecology, oncology, proctology and urology. The company has already received marketing authorization from the FDA for the XSense System and its cryoprobes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- IceCure Medical Awaits FDA Decision as ProSense® Gains Attention
- Is ICCM a Buy, Before Earnings?
- IceCure Medical Seeks to Expand in China with ProSense® Cryoablation System
- IceCure Medical files for approval of ProSense Cryoablation System in China
- Icecure Medical Announces Equity Distribution Agreement